Get the Stockscreener App
6.16
3.36%
0.20
After Hours:
6.07
-0.09
-1.46%
Immuneering Corp stock is traded at $6.16, with a volume of 1.62M.
It is up +3.36% in the last 24 hours and down -21.63% over the past month.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
See More
Previous Close:
$5.96
Open:
$5.98
24h Volume:
1.62M
Relative Volume:
1.05
Market Cap:
$256.07M
Revenue:
$317.00K
Net Income/Loss:
$-53.47M
P/E Ratio:
-3.2593
EPS:
-1.89
Net Cash Flow:
$-49.31M
1W Performance:
-5.23%
1M Performance:
-21.63%
6M Performance:
+377.52%
1Y Performance:
+166.67%
1-Day Range:
$5.805
$6.32
1-Week Range:
$5.805
$6.6499
52-Week Range:
$1.10
$10.08
Immuneering Corp Stock (IMRX) Company Profile
Name
Immuneering Corp
Sector
Industry
Phone
617-500-8080
Address
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Compare IMRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
6.16 | 376.90M | 317.00K | -53.47M | -49.31M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.90 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
470.27 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
576.42 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
815.61 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
316.15 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Mar-15-24 | Downgrade | Jefferies | Buy → Hold |
| Mar-15-24 | Reiterated | Needham | Buy |
| Mar-15-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-01-23 | Initiated | Needham | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Apr-19-23 | Upgrade | Mizuho | Neutral → Buy |
| Apr-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-30-23 | Initiated | Mizuho | Neutral |
| Feb-03-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-08-22 | Initiated | Chardan Capital Markets | Buy |
| Apr-01-22 | Initiated | Oppenheimer | Outperform |
| Jan-07-22 | Initiated | Piper Sandler | Overweight |
View All
Immuneering Corp Stock (IMRX) Latest News
Immuneering’s Cancer Drug Bets Deliver A Market-Beating Year - Finimize
Evaluating Immuneering Corporation with trendline analysisQuarterly Market Review & Real-Time Stock Price Movement Reports - newser.com
Immuneering Corporation stock outlook for YEARMarket Activity Summary & Accurate Entry/Exit Alerts - newser.com
How Immuneering Corporation stock valuations compare to rivalsJuly 2025 Action & Daily Profit Focused Stock Screening - newser.com
Is Immuneering Corporation stock ready for a breakoutJuly 2025 Action & AI Enhanced Trading Signals - newser.com
Will Immuneering Corporation stock outperform value stocksJuly 2025 Rallies & Stock Timing and Entry Methods - newser.com
Forecasting Immuneering Corporation price range with options dataJuly 2025 Fed Impact & Community Consensus Picks - newser.com
Key metrics from Immuneering Corporation’s quarterly data2025 Market WrapUp & Low Drawdown Investment Ideas - newser.com
Is it too late to sell Immuneering CorporationJuly 2025 Market Mood & Safe Swing Trade Setups - newser.com
Why Immuneering Corporation stock is in analyst buy zoneJuly 2025 Retail & Risk Adjusted Buy/Sell Alerts - newser.com
Can Immuneering Corporation stock sustain market leadershipLong Setup & Community Trade Idea Sharing - newser.com
Weiss Ratings Reiterates Sell (E+) Rating for Immuneering (NASDAQ:IMRX) - MarketBeat
Insider Stock Purchases: October 07, 2025 - Quiver Quantitative
Insider Buying: Immuneering (NASDAQ:IMRX) Director Purchases 7,500 Shares of Stock - MarketBeat
Will Immuneering Corporation stock outperform Nasdaq indexJuly 2025 Setups & Verified Momentum Stock Watchlist - newser.com
Analyzing recovery setups for Immuneering Corporation investorsMarket Activity Summary & Consistent Profit Focused Trading Strategies - newser.com
What to expect from Immuneering Corporation in the next 30 daysEarnings Performance Report & Free Community Supported Trade Ideas - newser.com
Will Immuneering Corporation stock benefit from commodity prices2025 Retail Activity & Weekly High Return Stock Opportunities - newser.com
Two new option listings and three option delistings on October 2nd - TipRanks
Immuneering Corporation (NASDAQ:IMRX) Receives $17.75 Consensus PT from Analysts - Defense World
Insider Stock Purchases: October 01, 2025 - Quiver Quantitative
Feinberg Peter buys Immuneering Corp (IMRX) shares for $52,730 - Investing.com India
Positive Trial Data Supports 43% Upside for Immuneering Corporation (IMRX) - Insider Monkey
Peter Feinberg Acquires 5,000 Shares of Immuneering (NASDAQ:IMRX) Stock - MarketBeat
Will Product Innovation Drive Rajasthan Gases Limited Stock in YEARInstitutional Buying Trends & Create Your Free Watchlist Instantly - earlytimes.in
11 Best Fast Money Stocks to Buy Now - Insider Monkey
Transcript : Immuneering CorporationSpecial Call - MarketScreener
Identifying reversal signals in Immuneering Corporation2025 Analyst Calls & Risk Managed Investment Signals - newser.com
Immuneering Corporation (NASDAQ:IMRX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Immuneering (NASDAQ:IMRX) Price Target Raised to $20.00 at Chardan Capital - Defense World
Immuneering Corporation's (NASDAQ:IMRX) last week's 13% decline must have disappointed individual investors who have a significant stake - Sahm
Immuneering to host call on pancreatic cancer treatment data By Investing.com - Investing.com Nigeria
Immuneering To Discuss Recently Announced Overall Survival Data From Phase 2A Clinical Trial Of Atebimetinib + Mgnp In First-Line Pancreatic Cancer Patients On September 29 - TradingView
MBX, uniQure among biotechs raising nine-figure sums: Public Equity Report - biocentury.com
Immuneering to host call on pancreatic cancer treatment data - Investing.com
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025 - The Manila Times
First-Line Pancreatic Cancer Trial Update: Immuneering to Present Survival Data for Atebimetinib + mGnP - Stock Titan
Immuneering (NASDAQ:IMRX) Price Target Raised to $30.00 at Oppenheimer - Defense World
Immuneering Corp Stock (IMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.09%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):